VivoSeq
Oncology

Uterine Cancer

29

Pipeline Programs↗

7

Active Trials↗

18

Companies Involved↗

Uterine Cancer is an emerging landscape with 29 programs across 18 companies. The most active players are Merck & Co., Vion Pharmaceuticals, Bristol-Myers Squibb. 2 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

6/100

Mech. Concentration

14/100

Completion Rate

69/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

2 programs

Phase 1V

Vion Pharmaceuticals

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 2A

Avyxa

2 programs

Phase 2Bayer logo

Bayer

2 programs

Phase 2G

Gynecologic Oncology Group

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

28 of 32 classified programs — the dominant modality here.

13%ALL OTHERSMonoclonal antibody26%Protein / enzyme26%

Small molecule leads; the ring shows all 32 classified programs, each share of the total. Modality classified for 100% of 32 pipeline programs.

Analysis

Trial Status

24

clinical trials

Completed11 · 46%
Terminated4 · 17%
Recruiting4 · 17%
Active, not recruiting3 · 13%
Withdrawn1 · 4%
Unknown status1 · 4%

Clinical Trials

Trial Activity

24 trials

Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer
Recruiting·National Institute of Cancerología·Phase 3·NCT06156514·140 enrolled
Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer
Recruiting·UUniversity Medical Center Groningen·Phase 2·NCT06180733·12 enrolled
[18F]FES PET/.CT in Uterine Cancer
Recruiting·—·Phase 2·NCT05916196·30 enrolled
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Recruiting·WWashington University School of Medicine·Phase 1·NCT06795009·36 enrolled
Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer
Active, not recruiting·UUniversity Health Network, Toronto·Phase 1·NCT06107868·6 enrolled
Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy
Active, not recruiting·National Cancer Institute (NCI)·Phase 1·NCT04494113·12 enrolled
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women (OvAR-Y): an In-Silico Feasibility Trial
Active, not recruiting·WWashington University School of Medicine·N/A·NCT06904365·10 enrolled
Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT00238121·56 enrolled
The Effects of Perioperative Dexmedetomidine Administration on Immune Suppression and Outcomes in Patients With Uterine Cancer Undergoing Radical Resection
Completed·YYonsei University·N/A·NCT02896413·100 enrolled
Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer
Completed·UUniversity Hospital, Ghent·Phase 2·NCT03192059·43 enrolled
Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility Study
Completed·UUniversity Medical Center Groningen·Phase 1·NCT04262089·10 enrolled
Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer
Completed·GGynecologic Oncology Group·Phase 2·NCT00112489·55 enrolled
A Study of Nivolumab in Selected Uterine Cancer Patients
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03241745·35 enrolled
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT01168232·42 enrolled
Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
Completed·GGynecologic Oncology Group·Phase 2·NCT00114218·28 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)